

RESEARCH ARTICLE

Open Access

Association of TPH-1 and TPH-2 gene polymorphisms with suicidal behavior: a systematic review and meta-analysis

Thelma Beatriz González-Castro¹, Isela Juárez-Rojop¹, María Lilia López-Narváez^{2,3} and Carlos Alfonso Tovilla-Zárate^{4*}

Abstract

Background: It is widely acknowledged that suicidal behavior (SB) has a genetic influence. As a consequence, molecular genetic studies have been mostly conducted on serotonergic genes. One of the most promising candidate genes of this system is tryptophan hydroxylase (TPH). Although there have been several positive studies associating TPH genes and SB, the evidence is not entirely consistent. Therefore, we performed a meta-analysis to gain a better understanding into this issue.

Methods: The meta-analysis was conducted with 37 articles of genetic association studies of TPH-1 (A218C and A779C) and TPH2 (G-703 T, A-473 T and G19918A) genes. To analyze the association of these variants with SB we used the following models: allelic, additive, dominant and recessive. In addition, we performed a sub-group analysis by Caucasian and Asian populations using the same four models.

Results: TPH-1 gene variants showed a positive significant association with SB, but only in the fixed effects models. With regard to TPH-2 gene variants we could not find an association with SB.

Conclusions: The study provides evidence that A218C/A779C TPH-1 variants may be a risk factor to manifest SB at the clinical level, which is in agreement with previously reported meta-analyses. With regard to G-703 T/A-473 T/G19918A TPH-2 variants, our up-to-date meta-analysis could not detect any significant association between those genetic variants and SB. However, these results should be interpreted with caution since further studies need to be undertaken using larger sample sizes in different ethnic populations to confirm our findings.

Keywords: Suicidal behavior, Systematic review, Meta-analysis, TPH-1 gene, TPH-2 gene

Background

Suicidal behavior (SB) is a leading cause of injury and death worldwide; it accounts for almost one million deaths annually and is the leading cause of death among individuals between 15 and 44 years of age [1-3]. Suicide has been defined as the act of intentionally ending one's own life. Nonfatal suicidal thoughts and behaviors are classified more specifically into three categories: suicide ideation (refers to thoughts and plans for ending one's life), suicide attempt (engagement in potentially self-injurious behavior with no lethal outcome) and completed suicide (the person ends with his/her life). There are several

measurements of past suicidal behavior, which basically consist in predicting future suicidal behavior, as well as to obtain information about history ideation, plans and/or attempts to commit suicide, among other data (e.g. DSM-IV diagnoses) [4-6].

A genetic influence in SB is now widely acknowledged and has received convincing support from familial, twin and adoption studies [7,8], together with molecular genetic studies mostly conducted on serotonergic candidate genes. Moreover, the evidence from these various genetic studies indicates that dysfunctions of the central serotonergic system are involved in the pathogenesis of suicidal behavior [9]. In this manner, of the several serotonin-related genes studied in relation to SB, one of the most promising is tryptophan hydroxylase (TPH) [10]. The principal reason for testing the association between TPH genes and SB

* Correspondence: alfonso_tovillaz@yahoo.com.mx

⁴División Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma de Tabasco, Ranchería Sur, Cuarta Sección, C.P. 86650 Comalcalco, Tabasco, México

Full list of author information is available at the end of the article

is that TPH is the first and rate-limiting step in the synthesis of the serotonin neurotransmitter [11]. TPH genes have been associated with low CSF 5-HIAA levels in healthy volunteers and have been suggested as a quantitative risk factor, in which a greater effect of the gene results in the intensification of serotonergic dysfunction associated with higher levels of anger and more severe suicidal acts [12,13].

With regard to the TPH enzyme there are two genes encoding it, both lie on intron seven: TPH-1, located on the human chromosome 11p15.3-14, has an approximate length of 29 kb and contains at least 11 exons and TPH-2 on chromosome 12q 21.1 covers a region of about 97 kb and comprises also 11 exons [14]. Thus, variations in TPH genes have prompted several researchers to conduct association genetic studies on TPH single-nucleotide polymorphisms (SNPs) [15]. Of the several different polymorphisms studied, most researches have focused on two SNPs in TPH1 [16]. The first polymorphism, A779C (rs1799913), was identified by single strand conformational analysis and comes mainly in two alternative forms or alleles TPH 779A and TPH 779C, referred to as U and L, respectively [17]. The second polymorphism, A218C (rs1800532), is in complete or strong linkage disequilibrium with A779C in various populations; both have been studied somewhat interchangeably [9]. With regard to TPH2 gene variants, the association with suicidal behavior is in progress and until now several SNPs have been studied [10]. However, the most common SNPs studied in connection with SB are rs4570625 (G-703 T), rs11178997 (A-473 T) and rs1386494 (G19918A) [18]. These SNPs have been selected for their functional relevance. As a result, the G-703 T polymorphism has been reported in higher number in suicidal depressed patients compared with healthy controls, whereas the A-473 T polymorphism has raised large interest for its possible effect on gene expression in the brainstem of depressed patients who committed suicide [19]. Finally, the G19918A polymorphism has been found in association with completed suicides [20].

Although there have been several positive studies associating TPH genes and SB the evidence is inconsistent. These inconclusive results are probably due to small sample sizes, different polymorphic markers used in the analysis, as well as variations in sampling strategies, mainly in the control groups, and the different ethnic populations assessed [21]. Although there are previous meta-analyses [18,22-25], we decided to undertake another study in which in larger number sample size and more rigorous selection criteria could give us a better understanding into this matter. The aims of the present study were to analyze the association of TPH-1 (A218C and A779C) and TPH2 (G-703 T, A-473 T and G19918A) genes with SB using a meta-analysis and to integrate the outcomes of the several genetic studies

included in this methodology by taking into account heterogeneity sources and the evaluation of possible bias in publication. Given that several authors have shown that the frequencies of TPH-1 and TPH-2 gene variants may be ethnic-dependent, we decided to perform a sub-group analysis by populations.

PICOT question

In population with suicidal behavior, what is the influence of TPH-1 and TPH2 genes variants in manifesting a clinical expression of suicidal behavior when compared to healthy subjects?

Methods

The research protocol of this analysis is available upon request. The meta-analysis and systematic review were performed by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria [26,27].


Identification and selection of publications

Data were obtained by searching in EBSCO and PubMed databases from May to Jun 2013. Relevant publications were identified using the following search terms: "TPH1 and suicidal behavior" (PubMed: 23; EBSCO: 17), "TPH2 and suicidal behavior" (PubMed: 28; EBSCO: 29), "TPH1 and suicide" (PubMed: 25; EBSCO: 17), "TPH2 and suicide" (PubMed: 46; EBSCO: 39), "Tryptophan hydroxylase and suicidal behavior" (PubMed: 90; EBSCO: 53). These words were combined to retrieve the summaries. The search also implicated the review of the bibliography cited at the end of the various research articles. To be selected, the publications had to meet the following criteria: (1) to be published in peer-reviewed journals, (2) to contain independent data, (3) to be case-control association studies in which the frequencies of three genotypes were clearly stated or could be calculated, (4) diagnosis of suicidal behavior of the patients in the study (suicide ideation, suicide attempt and completed suicide), and (5) the use of healthy individuals as controls. A final requirement was that the articles were written in English. The following polymorphisms were studied: A779C (rs1799913) and A218C (rs1800532) of the TPH-1 gene, and rs4570625 (G-703 T), rs11178997 (A-473 T), and rs1386494 (G19918A) of the TPH-2 gene.

Two researchers (González-Castro and Juárez-Rojop) working independently screened each of the titles, abstracts, and full texts to determine inclusion. When the researchers were in disagreement a third researcher (Tovilla-Zárate) was consulted.

Data extraction

The same authors mentioned above carefully extracted the information from all the included publications. They worked in an independent manner and in accordance



with the inclusion criteria listed above. The following data were obtained from each of the studies: authors, year of publication, region, number of cases and controls, age, gender, psychiatric diagnosis, number of males in the groups and ethnical origin of the participants. These data

were not always available for all the studies. In the cases of missing data, we contacted the respective authors to ask for the allele frequencies not included in the main text of the papers. One of the studies did not include a control group [28], but we made an adjustment accordingly based




Table 1 Descriptive characteristics in association studies on A218C/A779C TPH-1 gene variants and SB by populations

Reference	Location	Diagnosis	Number of males		Number		Genotypes		Alleles		P for HWE	
			Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
Caucasian population (A218C TPH-1 variant)												
Bellivier F. et al., 1998 [62]	France	SA and manic-depression	-	57	104	94	34/48/22	11/45/38	116/92	67/121	0.08	0.55
Geijer T. et al., 2000 [53]	Sweden	SA	57	64	165	98	30/87/48	13/47/38	147/183	73/123	1.00	0.43
Du L. et al., 2000 [54]	Canada	SC	-	-	35	84	6/24/5	13/52/19	36/34	78/90	0.04*	0.04*
Souery D. et al., 2001 [37]	Germany, Greece, Israel, Italy, Sweden, UK	SI and bipolar disorder	-	-	167	167	29/85/53	27/74/66	143/191	128/206	0.41	0.75
Abbar M. et al., 2001 [47]	France	SA	105	170	231	281	43/120/68	30/133/118	206/256	193/369	0.50	0.30
Zalsman G. et al., 2001 [40]	Israel	SA	40	74	84	172	16/34/34	41/85/46	66/102	167/178	0.89	0.17
Turecki G. et al., 2001 [39]	Canada	SC	-	-	101	129	18/48/35	18/71/40	84/118	107/151	0.15	0.83
Rujescu D. et al., 2002 [36]	Germany	SA and anger related traits	27	66	86	154	10/48/28	19/78/57	68/104	116/192	0.39	0.17
Rujescu D. et al., 2003 [24]	Germany	SA	52	-	147	326	18/81/48	40/155/131	117/177	235/417	0.63	0.08
Jernej B. et al., 2004 [34]	Croatia	SC	144	298	185	358	84/85/16	202/141/15	253/117	545/171	0.14	0.49
Stefulj J. et al., 2005 [16]	Croatia	SC	160	284	160	284	21/69/70	44/145/95	111/209	233/335	0.39	0.60
Stefulj J. et al., 2006 [46]	Croatia	SC	247	320	247	320	33/111/103	50/162/108	177/317	262/378	0.48	0.78
Viana M.M. et al., 2006 [48]	Brazil	SA, major depression, schizophrenia and alcoholism	142	36	248	63	45/125/78	7/31/25	215/281	45/81	0.78	0.79
Baud P. et al., 2009 [28]	Switzerland, France	SA	166	-	537	1027	99/256/182	181/483/363	454/260	845/1209	0.59	0.34
Wilson T. et al., 2009 [52]	USA	SA and bipolar disorder	-	39	71	101	13/44/14	22/43/36	70/72	87/115	0.22	0.05*
Saetre P. et al., 2010 [23]	Denmark, Norway, Sweden	SA and schizophrenia	-	845	825	1460	289/391/145	570/694/196	969/681	1834/1086	0.00*	0.63
Buttenschon H.N. et al., 2013 [41]	Denmark	SC	209	763	490	1027	80/228/182	181/843/363	388/592	845/1209	0.36	0.57
							868/1884/1131	1469/3282/1754			0.11	0.37
Asian population (A218C TPH-1 variant)												
Tsai S.J. et al., 1999 [55]	Taiwan	SA and mood disorders	-	-	41	200	17/15/9	33/113/54	49/33	179/221	0.06	0.19
Liu X. et al., 2006 [56]	China	SA	171	98	287	177	72/148/67	41/84/49	292/282	166/182	0.65	0.63
Yoon H.K. et al., 2008 [44]	Korea	SA and major depression	70	73	193	191	49/97/45	60/85/48	195/187	205/181	0.11	0.88
Kunugi H. et al., 1999 [42]	Japan	SA	-	95	46	208	10/29/7	55/105/48	49/43	215/201	1.00	0.13
Paik I. et al., 2000 [45]	Korea	SA and schizophrenia	-	124	27	236	04/12/11	66/116/54	20/34	248/224	0.89	1.00
Ono H., et al., 2000 [43]	Japan	SC	90	90	132	132	29/68/35	26/71/35	126/138	123/141	0.38	0.86
Hong C.J. et al., 2001 [35]	Taiwan	SA and schizophrenia	-	123	140	251	42/57/41	42/135/74	141/139	219/283	0.15	0.02*

Table 1 Descriptive characteristics in association studies on A218C/A779C TPH-1 gene variants and SB by populations (Continued)

Ohtani M. et al., 2004 [49]	Japan	SC	95	171	134	325	30/60/42 253/486/257	44/113/57 367/822/419	120/144	201/227	0.41	0.37
Caucasian population (A779C TPH-1 variant)												
Nielsen D.A. et al., 1998 [38]	USA	SI and alcoholism	-	232	102	232	17/57/28	49/106/77	91/113	204/260	0.28	0.23
Rotondo A. et al., 1999 [51]	Italy and USA	SA	-	153	97	153	12/50/35	33/68/52	74/120	215/201	0.25	0.51
Roy A. et al., 2001 [17]	Sweden	SC	-	-	24	158	02/12/20	35/86/37	16/332	156/160	0.33	1.00
Saetre P. et al., 2010 [23]	Denmark, Norway and Sweden	SA and schizophrenia	-	845	830	1464	290/391/149	570/691/203	971/689	1831/1097	0.00*	0.63
Pooley E.C. et al., 2003 [50]	UK	SA	52	138	129	329	20/67/42 341/577/274	44/135/150 731/1086/519	107/151	223/435	0.13 0.44	0.47 0.34
Asian population (A779C TPH-1 variant)												
Kunugi H. et al., 1999 [42]	Japan	SA	-	95	46	208	10/29/7	55/105/48	49/43	215/201	1.00	0.13
Ohtani M. et al., 2004 [49]	Japan	SC	95	171	134	325	30/59/42	45/138/82	119/143	228/302	0.38	0.29
Liu X., et al. 2006 [56]	China	SA	171	98	266	164	77/126/63 117/214/112	43/85/36 143/328/166	280/252	171/157	0.75 0.50	0.46 0.47

SA = Suicide attempt, SI = Suicide ideation, and SC = Suicide completion.* Non equilibrium of Hardy Weinberg.

Table 2 Descriptive characteristics in association studies on G-703 T/A473T/G19918A TPH-2 gene variants and SB by populations

Reference	Location	Diagnosis	Number of males		Number		Genotypes		Alleles		P for HWE	
			Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
							GG/TG/TT	GG/TG/TT	T/G	T/G		
Caucasian population (G-703 T TPH-2 variant)												
Zhou Z. et al., 2005 [61]	USA	SA and major depression	150	196	150	196	106/40/4	132/58/6	252/48	322/70	1.00	1.00
Zill P. et al., 2007 [60]	Germany	SA and alcoholism	-	164	102	305	61/36/5	191/101/13	158/46	483/127	1.00	1.00
Stefulj J. et al., 2011 [57]	Croatia	SC	291	280	291	280	181/96/14	183/80/17	458/124	446/114	0.06	0.72
							348/172/23	506/239/36			0.78	0.26
Asian population (G-703 T TPH-2 variant)												
Mouri K. et al., 2009 [58]	Japan	SC	156	162	234	260	62/117/55	80/128/52	241/227	288/232	1.00	1.00
Yoon H.K. et al., 2008 [44]	Korea	SA and major depression	82	80	181	176	58/81/42	34/82/60	197/165	150/202	0.18	0.53
							120/198/97	114/210/112			0.37	0.44
Reference	Location	Diagnosis	Number of males		Number		Genotypes		Alleles		P for HWE	
			Cases	Cases	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
							AA/AT/TT	AA/AT/TT	A/T	A/T		
Caucasian population (A-473 T TPH-2 variant)												
Zhou Z. et al., 2005 [61]	USA	SA and major depression	150	196	150	196	0/14/136	0/15/181	14/286	15/377	1.00	1.00
Zupanc T. et al., 2011 [19]	Slovenia	SC and alcoholism	-	-	383	222	0/42/341	2/31/189	42/724	35/409	0.61	0.63
							0/56/177	2/46/370			0.36	0.65
Asian population (A-473 T TPH-2 variant)												
Mouri K. et al., 2009 [58]	Japan	SC	156	162	234	260	2/44/188	3/48/209	48/420	54/466	1.00	0.74
Reference	Location	Diagnosis	Number of males		Number		Genotypes		Alleles		P for HWE	
			Cases	Cases	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
							GG/GA/AA	GG/GA/AA	G/A	G/A		
Caucasian population (G19918A TPH-2 variant)												
Zill P. et al., 2004 [20]	Germany	SC	191	138	263	266	195/63/5	166/88/12	453/73	420/112	1.00	1.00
Zill P. et al., 2007 [60]	Germany	SA and alcoholism	-	164	102	305	4/31/67	12/98/195	39/165	122/488	0.75	1.00
Must A. et al., 2009 [59]	Estonia	SC	298	327	288	327	206/75/7	242/79/6	487/89	563/91	1.00	1.00
Buttenschon H.N. et al., 2013 [41]	Denmark	SC	209	763	553	1033	396/150/7	743/268/22	942/169	1754/312	0.09	0.08
							801/319/86	1163/533/235			0.06	0.09
Asian population (G19918A TPH-2 variant)												
K. Mouri et al., 2009 [58]	Japan	SC	156	162	234	260	219/15/0	239/21/0	453/234	499/260	1.00	1.00

SA = Suicide attempt, SI = Suicide ideation, and SC = Suicide completion.


Table 3 Meta-analysis of case-control studies on A218C/A779C TPH-1 gene variants in patients with suicidal behavior

Model analysis		A218C		P value of Q test	P value of Egger's test	A779C		P value of Q test	P value of Egger's test
		Random effects	Fixed effects			Random effects	Fixed effects		
		OR (CI 95%)	OR (CI 95%)			OR (CI 95%)	OR (CI 95%)		
All populations									
Allelic	With heterogeneity	1.10 (0.98-1.22)	1.09 (1.04-1.16)	<0.001	0.85	0.96 (0.76-1.22)	1.09 (0.99-1.21)	<0.0001	0.46
	Without heterogeneity	1.02 (0.94-1.11)	1.01 (0.95-1.08)	0.11	0.27	0.97 (0.85-1.11)	0.97 (0.85-1.11)	0.43	0.24
Additive	With heterogeneity	1.22 (0.98-1.52)	1.22 (1.09-1.37)	<0.00001	0.95	1.02 (0.67-1.54)	1.29 (1.04-1.59)	0.001	0.25
	Without heterogeneity	1.06 (0.90-1.24)	1.04 (0.92-1.19)	0.15	0.50	0.92 (0.71-1.19)	0.92 (0.71-1.19)	0.42	0.11
Dominant	With heterogeneity	1.16 (0.96-1.41)	1.16 (1.07-1.27)	<0.0001	0.93	1.17 (0.75-1.83)	1.43 (1.21-1.69)	<0.0001	0.07
	Without heterogeneity	1.04 (0.91-1.18)	1.02 (0.93-1.13)	0.07	0.65	1.00 (0.82-1.22)	1.00 (0.82-1.22)	0.47	0.73
Recessive	With heterogeneity	1.10 (0.94-1.28)	1.04 (0.95-1.15)	0.0005	0.15				
	Without heterogeneity	0.97 (0.87-1.08)	0.97 (0.87-1.08)	0.97	0.80	0.88 (0.72-1.08)	0.90 (0.76-1.06)	0.23	0.23
Caucasian population									
Allelic	With heterogeneity	1.12 (0.971-1.29)	1.10 (1.04-1.17)	<0.0001	0.69	0.90(0.62-1.30)	1.11(0.98 1.25)	<0.0001	0.60
	Without heterogeneity	1.01(0.91-1.13)	1.00 (0.93-1.08)	0.006	0.36	0.95(0.78-1.14)	0.95(0.78 1.14)	0.58	0.25
Additive	With heterogeneity	1.25 (0.95-1.64)	1.22 (1.07-1.39)	<0.0001	0.73	0.89(0.46-1.71)	1.36 (1.05 1.75)	<0.0001	0.80
	Without heterogeneity	1.05(0.87-1.27)	1.03 (0.88-1.19)	0.18	0.22	0.80(0.55-1.16)	0.80(0.55-1.16)	0.69	0.94
Dominant	With heterogeneity	1.24(0.96-1.59)	1.20 (1.09-1.32)	<0.0001	0.68	1.17(0.75-1.83)	1.43(1.21-1.69)	<0.0001	0.40
	Without heterogeneity	1.12(0.97-1.28)	1.10 (0.97-1.25)	0.35	0.06	1.09(0.83-1.44)	1.09(0.83 -1.44)	0.77	0.58
Recessive	With heterogeneity	1.02 (0.841-1.24)	0.97 (0.87-1.09)	<0.0001	0.34	0.81(0.67-0.98)	0.81(0.670-0.98)	<0.0001	0.30
	Without heterogeneity	0.95 (0.84-1.06)	0.95 (0.84-1.06)	0.66	0.20	0.68(0.51-0.91)	68(0.51-0.91)	0.71	0.31
Asian population									
Allelic	With heterogeneity	1.06(0.89-1.27)	1.06 (0.94-1.20)	0.04	0.72	1.05(0.88 1.27)	1.05(0.88-1.27)	0.93	0.84
	Without heterogeneity	1.11(0.95-1.28)	1.10 (0.97 1.24)	0.21	0.30				
Additive	With heterogeneity								
	Without heterogeneity	1.17(0.83-1.65)	1.18 (0.93 1.50)	0.06	0.69	1.15(0.79-1.68)	1.15(0.79-1.68)	0.83	0.76
Dominant	With heterogeneity					0.99(0.73-1.35)	0.99(0.73-1.35)	0.45	0.10
	Without heterogeneity	1.01(0.82-1.25)	1.01(0.84-1.23)	0.31	0.27	0.92(0.67-1.28)	0.92(0.67-1.28)	0.88	1.000
Recessive	With heterogeneity	1.18(0.81-1.72)	1.19(0.97-1.45)	0.002	0.89	1.16(0.86-1.58)	1.16(0.86-1.58)	0.40	0.54
	Without heterogeneity	0.94(0.74-1.18)	0.94 (0.74-1.18)	0.52	0.27				

Bold text: Statistically significant.

on the other studies in the literature that included a control group [29]. Briefly, we calculated the weighted frequency for a particular genotype from studies that included controls and applied it to the study without a control

group. We considered the number of the “virtual” control group equal to the number of patients in the specific study. Then the hypothetical number of subjects with the particular genotype frequency was assigned in proportion to the



percentage of the same genotype which was obtained from the weighted analysis [30,31]. The outcomes of the meta-analysis were built by taking into consideration the categories reported in previously published studies [32,33].

Figure 1 shows the stages of the meta-analysis. The combined search included 367 potentially relevant articles. Finally, 37 articles were obtained after discarding overlapping references that did not agree with the inclusion criteria [16,17,19-24,28,34-61]; Figure 2 shows the articles published at this stage of the analysis. In the case of

TPH-1 gene variants (A218C and A779C), 5683 cases and 11652 controls were involved, whereas for the TPH-2 gene variants (G-703 T, A-473 T and G19918A) 4196 cases and 5990 controls were considered (Tables 1 and 2, respectively).

Data analysis

For the meta-analysis procedures we used the EPIDAT 3.1 program (http://www.sergas.es/MostrarContidos_N3_T01.aspx?IdPaxina=62715). This software is freely available for





Figure 4 Egger's funnel plots indicating publication bias in studies on suicidal behavior and the A218C variant without heterogeneity, using the following models: A) Allelic; B) Additive; C) Dominant, and D) Recessive models.

epidemiologic analysis of tabulated data. Data were analyzed with the random-effects and fixed effects models following the reports in the literature [63-65]. Sample heterogeneity was analyzed with the Dersimonian and Laird's Q test. Q test results were complemented with graphs to help the visualization of those studies favoring heterogeneity. The studies outside the heterogeneity curve were excluded. The results of the meta-analysis are expressed as odds ratios (ORs). Pooled ORs were calculated respectively for each of the models used, viz.: allelic (Example: A vs. C), additive (AA vs. CC), dominant (AA + AC vs. CC), and recessive (AA vs. AC + CC). Also,

we analyzed TPH1 and TPH2 gene variants by Caucasian and Asian populations. To address the problem of publication bias, the Egger's test and funnel plots were calculated with the EPIDAT 3.1 software. This plotting standardizes the effect of each of the published studies on the vertical axis and its correspondent precision on the horizontal axis. Also, we evaluated publication bias using the GRADE approach and assessed the risk for bias. Finally, a chi-squared (χ^2) analysis was used to calculate the Hardy-Weinberg equilibrium to evaluate genotype distribution. Studies deemed for inclusion in the systematic review were scored for methodological



quality using the Newcastle-Ottawa Assessment Scale (NOS). A score of six or more was taken as the cut-off point to distinguish high from low quality studies [66] (see Additional file 1).

Results

We measured the Hardy-Weinberg equilibrium (HWE) in both groups (cases and controls) for all the samples of TPH genes; we also explored all populations in a combined way. Results are shown in Tables 1 and 2.

TPH-1 gene variants

A218C polymorphism

Firstly, an analysis of the variant A218C (rs1800532) of the TPH-1 gene was performed. In this study we evaluated the role of this variant in several models: allelic, additive, dominant and recessive. Also, we considered the Caucasian and Asian populations separately, using the same four models. And as in a previous meta-analysis [18,22-25], we found a positive association of A218C variant with SB in the fixed effects model, but not in the random effects




Figure 6 Egger's funnel plots indicating publications bias in studies on suicidal behavior and the A779C variant without heterogeneity, using the following models: A) Allelic; B) Additive; C) Dominant, and D) Recessive models.

model. Our results are presented in Table 3. Figures 3 and 4 present the forest plots and Egger's test of the same four models previously mentioned (allelic, additive, dominant and recessive).

A779C polymorphism

With this variant we conducted the same analyses than in the previous variant gene (A218C). We observed a significant association with suicidal behavior, using the fixed effects model. This analysis was extended to Caucasian and Asian populations treated separately. Table 3 shows in more detail the analysis of this variant gene in all the models tested (allelic, additive, recessive and dominant). Figures 5 and 6 present forest plots and Egger's tests in the same models.

TPH-2 gene variants

G703T polymorphism

The first variant analyzed was the G-703 T (rs4570625) polymorphism. Initially, we explored the association of the G allele and patients with SB; we did not find significant differences (Random effects: OR: 1.02; 95% CI 0.85-1.22; $p(Z) = 0.99$). We observed heterogeneity in all studies ($Q = 12.43$; $df = 6$; $p = 0.04$). The Egger's test provided no evidence of publication bias ($t = 0.04$; $df = 5$; $p = 0.96$) (see Additional file 1). Next, we excluded the study by Yoon and Kim [44], based on heterogeneity, and still we

could not find any significant differences (Random effects: OR: 0.93; 95% CI 0.81-1.06; $p(Z) = 0.70$; Figure 7A; Q test = 1.73; $df = 5$; $p = 0.88$). Also, there was no evidence of publication bias (Egger's test: $t = 1.01$, $df = 4$; $p = 0.36$; Figure 8A). The same results were found when we used the additive model without heterogeneity (Random effects: OR: 0.88; 95% CI 0.65-1.20; $p(Z) = 0.45$; Figure 7B; Q test = 1.65; $df = 6$; $p = 0.89$). No evidence of publication bias was encountered (Egger's test $t = 1.03$; $df = 5$; $p = 0.36$; Figure 8B). We did not find any significant differences when we used the dominant model without heterogeneity either (Random effects: OR: 1.07; 95% CI 0.84-1.38; $p(Z) = 0.76$; Figure 7C; Q test = 6.43; $df = 6$; $p = 0.37$). Similarly, no evidence of publication bias was observed (Egger's test: $t = 0.24$, $df = 5$; $p = 0.83$; Figure 8). Finally, the same negative results were found in the recessive model without heterogeneity (Random effects: OR: 0.91; 95% CI 0.76-1.09; $p(Z) = 0.45$; Q test = 1.76; $df = 6$; $p = 0.88$; Figure 7D). No evidence of publication bias was encountered (Egger's test: $t = 0.46$; $df = 5$; $p = 0.66$; Figure 8D). In addition, we conducted the same analyses using the allelic, additive, dominant and recessive models in Asian and Caucasian populations, separately. However, we could not find any significant differences (Table 4).

A473T polymorphism

Also, we conducted an analysis of allele A of the A-473 T (rs11178997) polymorphism in association with SB and




Figure 7 Odds ratios and forest plots of the G-703 T TPH-2 variant in overall studies without heterogeneity, using the following models: A) Allelic; B) Additive; C) Dominant, and D) Recessive.




Figure 8 Egger's funnel plots indicating publication bias in studies on suicidal behavior and the G-703 T TPH-2 variant without heterogeneity, using the following models: A) Allelic; B) Additive; C) Dominant, and D) Recessive.

we found the same negative results with heterogeneity (Random effects: OR: 0.89; 95% CI 0.63-1.26; $p(Z) = 0.98$; Q test = 18.81 df = 5; $p = 0.002$). No evidence of publication bias was found (Egger's test $t = 0.83$, df = 4; $p = 0.44$). Next, we eliminated heterogeneity by excluding the study by Zhou et al. [61] in a Caucasian population (Random effects: OR: 0.76; 95% CI 0.61-0.95; $p(Z) = 0.80$; Q test = 4.54; df = 4; $p = 0.33$; Figure 9A) and found no significant differences. Besides, we did not encounter evidence of

publication bias (Egger's test: $t = 1.04$; df = 3; $p = 0.37$; Figure 10A). When we used the additive model, we excluded the studies by Zupanc et al. [19] and Zhou et al. [61] in the Caucasian population given that some frequencies were equal to zero. Still, we did not find any significant differences without heterogeneity (Random effects: OR: 1.00; 95% CI 0.52-1.93; $p(Z) = 0.73$; Figure 9B; Q test = 2.91; df = 3; $p = 0.40$); also we did not encounter evidence of publication bias (Egger's test: $t = 0.36$, df = 2; $p = 0.74$;

Table 4 Meta-analysis of case-control studies on G-703 T/ A-473 T/G19918A TPH-2 gene variants and SB by populations

Model analysis		G703T		P value of Q test	P value of Egger's test	A473T		P value of Q test	P value of Egger's test	G19918A		P value of Q test	P value of Egger's test
		Random effects OR (CI 95%)	Fixed effects OR (CI 95%)			Random effects OR (CI 95%)	Fixed effects OR (CI 95%)			Random effects OR (CI 95%)	Fixed effects OR (CI 95%)		
Caucasian population													
Allelic	With heterogeneity	0.95(0.79-1.14)	0.95(0.79-1.14)	0.91	0.72	0.95(0.79-1.14)	0.95(0.79-1.14)	0.91	0.72	1.12(0.88-1.43)	1.09(0.95-1.25)	0.04	0.59
	Without heterogeneity									0.99(0.85-1.16)	0.99(0.851.16)	0.52	0.57
Additive	With heterogeneity	1.03(0.66-1.62)	1.03(0.6-61.62)	0.84	0.56	1.03(0.66-1.62)	1.03(0.66-1.62)	0.84	0.56	1.45(0.87-2.40)	1.45(0.87-2.40)	0.44	0.95
	Without heterogeneity												
Dominant	With heterogeneity	1.05(0.68-1.62)	1.05(0.68-1.62)	0.79	0.79	1.05(0.68-1.62)	1.05(0.68-1.62)	0.79	0.79	1.18(0.79-1.76)	1.14(0.80-1.64)	0.35	0.33
	Without heterogeneity												
Recessive	With heterogeneity	0.91(0.72-1.15)	0.91(0.72-1.15)	0.86	0.54	0.91(0.72-1.15)	0.91(0.72-1.15)	0.86	0.54	1.15(0.86-1.55)	1.09(0.93-1.29)	0.06	0.59
	Without heterogeneity									0.98(0.81-1.18)	0.98(0.81-1.18)	0.60	0.52
Asian population													
Allelic	With heterogeneity	1.08(0.78-1.50)	1.08(0.92-1.27)	0.01	0.93								
	Without heterogeneity	0.91(0.75-1.11)	0.91(0.75-1.11)	0.47	0.58								
Additive	With heterogeneity	1.14(0.57-2.27)	1.14(0.81-1.60)	0.01	0.99								
	Without heterogeneity	0.78(0.51-1.17)	0.78(0.511.17)	0.78	0.29								
Dominant	With heterogeneity	1.09(0.82-1.44)	1.09(0.82-1.44)	0.11	0.94								
	Without heterogeneity												
Recessive	With heterogeneity	1.13 (0.74-1.70)	1.11(0.87-1.41)	0.03	0.86								
	Without heterogeneity	0.93(0.70-1.22)	0.93(0.70-1.22)	0.48	0.94								




Figure 10B). A negative result was also found for the dominant model without heterogeneity (Random effects: OR: 1.01; 95% CI 0.76-1.34; $p(Z) = 0.70$; Figure 9C; Q test = 10.46; $df = 5$; $p = 0.06$); no evidence of publication bias was encountered (Egger's test: $t = 1.74$; $df = 4$; $p = 0.15$; Figure 10C). The same negative results were obtained with the recessive model without heterogeneity excluding the studies by Zupanc et al. [19] and Zhou et al. [61] in the Caucasian population because some frequencies were equal to zero (Random effects: OR: 1.01; 95% CI 0.53-1.93; $p(Z) = 0.73$; Figure 9D; Q test = 2.33; $df = 3$; $p = 0.50$); there was no evidence of publication bias (Egger's test: $t = 0.31$; $df = 2$; $p = 0.78$; Figure 10D). In addition, with regard to the analysis of the A-473 T variant of the TPH-2 gene in relation to SB, we conducted an analysis in the Caucasian population, using the same four models as above and could not find any significant differences (Table 4).

G19918A polymorphism

Finally, the G19918A (rs1386494) polymorphism was the last variant studied in association with SB. When we analyzed allele G vs allele A, we could not find any significant differences in the analysis without heterogeneity (Random effects: OR: 1.09; 95% CI 0.91-1.31; $p(Z) = 0.98$; Figure 11A; Q test = 10.32; $df = 5$; $p = 0.06$); we found no evidence of publication bias (Egger's test: $t = 0.78$; $df = 4$; $p = 0.47$; Figure 12A). Subsequently, we performed an analysis with the additive model without heterogeneity

(Random effects: OR: 1.45; 95% CI 0.87-2.40; $p(Z) = 0.80$; Figure 11B; Q test = 3.70; $df = 4$; $p = 0.44$); we found no evidence of publication bias (Egger's test: $t = 0.09$; $df = 3$; $p = 0.95$, Figure 12B). The same negative outcome was found when using the dominant model without heterogeneity (Random effects: OR: 1.18; 95% CI 0.79-1.76; $p(Z) = 0.80$; Figure 11C; Q test = 4.38; $df = 4$; $p = 0.35$); no evidence of publication bias was found (Egger's test: $t = 1.14$; $df = 3$; $p = 0.33$; Figure 12C). The same result was obtained with the recessive model without heterogeneity (Random effects: OR: 1.16; 95% CI 0.90-1.50; $p(Z) = 0.45$; Figure 11D; Q test = 9.12; $df = 5$; $p = 0.10$); no evidence of publication bias was encountered (Egger's test: $t = 0.74$; $df = 4$; $p = 0.49$; Figure 12D). Finally, we conducted an analysis in the Caucasian population separately using the same four models as in the other polymorphism, and could not find any significant differences (Table 4).

Discussion

In this study, we explored the association of THP-1 and TPH-2 gene polymorphisms with suicidal behavioral. We found an association between A218C/ATT9C polymorphism of TPH1 and suicidal behavior. However, we could not find an association between TPH2 gene variants and this behavior. To our knowledge, this is the first study evaluating TPH2 gene variants and suicidal behavior.

Suicide has become a serious problem around the world. Various published studies show the search for possible genetic markers that could help in the early





Figure 10 Egger's funnel plots indicating publication bias in studies on suicidal behavior and the A-473 T TPH-2 variant without heterogeneity, using the following models: A) Allelic; B) Additive; C) Dominant, and D) Recessive.

detection and prevention of suicidal behavior [13,67,68]. One possible mechanism by which genetic factors may affect the risk for suicide is through the control of serotonergic neurotransmission. TPH genes have been proposed as the main candidate genes in association studies on suicidal behavior, given that the TPH enzyme is a rate-limiting step in serotonin biosynthesis. Despite the increasing amount of genetic association studies on SB,

the results are inconclusive. Therefore, we performed a meta-analysis in order to evaluate the association of TPH-1 and TPH-2 genes with SB in which we integrated the outcomes of the different polymorphic markers and different ethnic groups. Initially, although variants A218C (rs1800532) and A779C (rs1799913) of the TPH-1 gene have been studied in relation to suicidal behavior in different meta-analyses [18,22-25], we analyzed the TPH-1 gene



in patients with SB. The evaluated variants of this gene were A779C (rs1799913) and A218C (rs1800532); these two polymorphisms are the most studied of the TPH-1 gene and with interesting outcomes. We not only analyzed allele A vs allele C, but also evaluated the association using three other models: additive, dominant and recessive in a pool population that combined the genetic studies of TPH-1 variants. In addition, we performed a sub-group analysis in Caucasian and Asian populations separately to evaluate the association of A779C (rs1799913) and A218C (rs1800532) polymorphisms with SB using the same four models. Our results are in agreement with previous meta-analyses [18,22-25]. These studies report a strong association with SB using the fixed effects model. In the present meta-analysis we also found an association when we used the fixed effects model, but not with the random effects model. However, this result should be taken with caution because the random effects model is more conservative than the fixed effects one. The latter assumes the same true genetic effects, and the former supposes normally distributed effects and parametrizes inter-studies variations. To get a clearer panorama of the possible role of these variants in SB, we summarized the results of our analyses in Tables 3 and 4. The evidence suggests that TPH-1 A218C/A779C polymorphisms may be associated with increased susceptibility to present SB clinically.

On the other hand, to explore the association of SB with TPH-2 gene, we chose rs4570625 (G-703 T), rs11178997 (A-473 T) and rs1386494 (G19918A) variants, given their functionality and the extensive amount of studies evaluating these polymorphisms in association with SB. We

performed the analysis with the same four models used for the TPH1-gene: allelic, additive, dominant, and recessive. We also conducted a sub-group analysis in the Caucasian and Asian populations utilizing the same previously mentioned models. In the present study we could not find any association in any of the models, but we found a slight protective effect concerning polymorphism A-473 T toward suicidal behavior in the recessive model (Random effects: OR: 0.76; 95% CI 0.61-0.95; $p(Z) = 0.80$; Q test = 4.54; df = 4; $p = 0.33$); no evidence of publication bias was encountered (Egger's test: $t = 1.04$; df = 3; $p = 0.37$).

There are several explanations for the present outcomes concerning the lack of association of TPH-2 variants with SB. First, the criteria used in the selection of the control groups differ among studies. Second, although the subjects were patients with SB, there were differences in the diagnoses (attempted, ideation and completed suicide, and exclusion criteria of neuropsychiatric diseases, among other factors). For example, Souery et al. [37] work with patients with bipolar disorder that present SB, Yoon and Kim [44] with depressive subjects and SB, Paik et al. [45] with schizophrenic patients, and Turecki et al. [39] with suicide completers only. Other possibility is genetic heterogeneity: some authors have shown that the distribution of the frequencies of TPH-2 variants may depend on ethnicity. Therefore, we evaluated the association of TPH2 variants with SB in several populations. The fourth explanation considers the presence of other genes which may interact with TPH-2 to increase the risk to present SB clinically. We also want to emphasize the relevance of employing larger sample




Figure 12 Egger's funnel plots indicating publication bias in studies on suicidal behavior and the G19918A TPH-2 variant without heterogeneity, using the following models: A) Allelic; B) Additive; C) Dominant, and D) Recessive.

sizes to enable the observation of more conclusive results.

This study has some limitations. First, we performed the present meta-analysis based only on published studies. We considered that by selecting only published results, we ensured that our meta-analysis excluded poorly designed studies. Second, although the present analysis involves a large number of studies and genetic variants, it is relatively small in comparison with other meta-analysis on different

diseases. Also, we could not perform an analysis including suicide ideation, suicide attempt, or completed suicide. Other limitation is that we did not stratify the analysis by gender because it was not always possible to obtain all the data from the reports or directly from the authors. Also, we did not perform the analysis of all the variants of the TPH-2 gene in the Asian population because there were not enough studies. Sixth, we did not evaluate SB endophenotypes or psychopathologies which could increase

the risk for suicidal behavior. One last comment: is that although there are previous meta-analyses evaluating the association of the TPH-1 gene (A218C and A779C variants) and SB, our study contains more recent data and the use of various types of models to perform the analysis.

Conclusion

In summary, we performed a meta-analysis to assess the association of A779C (rs1799913) and A218C (rs1800532) variants of the TPH-1 gene, and rs4570625 (G-703 T), rs11178997 (A-473 T), and rs1386494 (G19918A) of the TPH-2 gene with SB. Our analysis of TPH-1 provided evidence that A218C/A779C TPH-1 variants may be risk factors to present SB, which is in agreement with previously reported meta-analyses [18,22-25]. With regard to G-703 T/A-473 T/G19918A TPH-2 variants, our updated meta-analysis did not detect any significant association with patients presenting SB. However, these results should be interpreted with caution because not all the models detected this association and the sample size may be just enough to detect small effects of the polymorphisms. Further studies with larger samples in different ethnic populations need to be undertaken to confirm our findings.

Additional file

Additional file 1: Table S1. Summary finding of studies association between TPH1 gene variants and suicidal behavior. **Table S2.** Methodological quality of TPH1 gene variants studies association included based on the Newcastle-Ottawa scale.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

TZC and GCTB conceived the study, participated in its design and helped to draft the manuscript. TZC, JRI, and LNML helped to perform the statistical analysis and to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We want to thank the support of grants UJAT-DAMC-2012-02 from the University of Tabasco and CONACYT CB2012-177459.

Author details

¹División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, México. ²CIGEN, Centro de Investigación Genómica, Comalcalco, Tabasco, México. ³Hospital General de Yajalón, Yajalón, Chiapas, México. ⁴División Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma de Tabasco, Ranchería Sur, Cuarta Sección, C.P. 86650 Comalcalco, Tabasco, México.

Received: 28 January 2014 Accepted: 27 June 2014

Published: 8 July 2014

References

1. Bondy B, Buettner A, Zill P: **Genetics of suicide.** *Mol Psychiatry* 2006, **11**(4):336-351.
2. Souery D, Oswald P, Linkowski P, Mendlewicz J: **Molecular genetics in the analysis of suicide.** *Ann Med* 2003, **35**(3):191-196.
3. Baldessarini RJ, Hennen J: **Genetics of suicide: an overview.** *Harv Rev Psychiatry* 2004, **12**(1):1-13.
4. Lee DH, Noh EC, Kim YC, Hwang JY, Kim SN, Jang JH, Byun MS, Kang DH: **Risk factors for suicidal ideation among patients with complex regional pain syndrome.** *Psychiatry Investig* 2014, **11**(1):32-38.
5. Lin SK, Hung TM, Liao YT, Lee WC, Tsai SY, Chen CC, Kuo CJ: **Protective and risk factors for inpatient suicides: a nested case-control study.** *Psychiatry Res* 2014, **217**(1-2):54-59.
6. Weiland TJ, Cotter A, Jelinek GA, Phillips G: **Suicide risk assessment in Australian emergency departments: assessing clinicians' disposition decisions.** *Psychiatry J* 2014, **2014**:943574.
7. Lester D: **Genetics, twin studies, and suicide.** *Suicide Life Threat Behav* 1986, **16**(2):274-285.
8. Voracek M, Loibl LM: **Genetics of suicide: a systematic review of twin studies.** *Wien Klin Wochenschr* 2007, **119**(15-16):463-475.
9. Koller G, Engel RR, Preuss UW, Karakesisoglou A, Zill P, Bondy B, Soyka M: **Tryptophan hydroxylase gene 1 polymorphisms are not associated with suicide attempts in alcohol-dependent individuals.** *Addict Biol* 2005, **10**(3):269-273.
10. Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC: **No association of the tryptophan hydroxylase gene with bipolar affective disorder, unipolar affective disorder, or suicidal behaviour in major affective disorder.** *Am J Med Genet* 1998, **81**(3):245-247.
11. New AS, Gelernter J, Yovell Y, Trestman RL, Nielsen DA, Silverman J, Mitropoulou V, Siever LJ: **Tryptophan hydroxylase genotype is associated with impulsive-aggression measures: a preliminary study.** *Am J Med Genet* 1998, **81**(1):13-17.
12. El-Sayed AM, Haloossim MR, Galea S, Koenen KC: **Epigenetic modifications associated with suicide and common mood and anxiety disorders: a systematic review of the literature.** *Biol Mood Anxiety Disord* 2012, **2**(1):2045-5380.
13. Antypa N, Serretti A, Rujescu D: **Serotonergic genes and suicide: a systematic review.** *Eur Neuropsychopharmacol* 2013, **23**(10):1125-1142.
14. Bennett PJ, McMahon WM, Watabe J, Achilles J, Bacon M, Coon H, Grey T, Keller T, Tate D, Tcaciuc I, Workman J, Gray D: **Tryptophan hydroxylase polymorphisms in suicide victims.** *Psychiatr Genet* 2000, **10**(1):13-17.
15. Booij L, Turecki G, Leyton M, Gravel P, Lopez De Lara C, Diksik M, Benkelfat C: **Tryptophan hydroxylase(2) gene polymorphisms predict brain serotonin synthesis in the orbitofrontal cortex in humans.** *Mol Psychiatry* 2012, **17**(8):809-817.
16. Stefulj J, Kubat M, Balija M, Skavic J, Jernej B: **Variability of the tryptophan hydroxylase gene: study in victims of violent suicide.** *Psychiatry Res* 2005, **134**(1):67-73.
17. Roy A, Rylander G, Forslund K, Asberg M, Mazzanti CM, Goldman D, Nielsen DA: **Excess tryptophan hydroxylase 17 779C allele in surviving cotwins of monozygotic twin suicide victims.** *Neuropsychobiology* 2001, **43**(4):233-236.
18. Li D, He L: **Further clarification of the contribution of the tryptophan hydroxylase (TPH) gene to suicidal behavior using systematic allelic and genotypic meta-analyses.** *Hum Genet* 2006, **119**(3):233-240.
19. Zupanc T, Pregelj P, Tomori M, Komel R, Paska AV: **TPH2 polymorphisms and alcohol-related suicide.** *Neurosci Lett* 2011, **490**(1):78-81.
20. Zill P, Buttner A, Eisenmenger W, Moller HJ, Bondy B, Ackenheil M: **Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims.** *Biol Psychiatry* 2004, **56**(8):581-586.
21. Haghighi F, Bach-Mizrachi H, Huang YY, Arango V, Shi S, Dwork AJ, Rosoklija G, Sheng HT, Morozova I, Ju J, Russo JJ, Mann JJ: **Genetic architecture of the human tryptophan hydroxylase 2 Gene: existence of neural isoforms and relevance for major depression.** *Mol Psychiatry* 2008, **13**(8):813-820.
22. Bellivier F, Chaste P, Malafosse A: **Association between the TPH gene A218C polymorphism and suicidal behavior: a meta-analysis.** *Am J Med Genet B Neuropsychiatr Genet* 2004, **1**(1):87-91.
23. Saetre P, Lundmark P, Wang A, Hansen T, Rasmussen HB, Djurovic S, Melle I, Andreassen OA, Werge T, Agartz I, Hall H, Terenius L, Jonsson EG: **The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: a multi-centre case-control study and meta-analysis.** *Am J Med Genet B Neuropsychiatr Genet* 2010, **153B**(2):387-396.
24. Rujescu D, Giegling I, Sato T, Hartmann AM, Moller HJ: **Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis.** *Biol Psychiatry* 2003, **54**(4):465-473.

25. Clayden RC, Zaruk A, Meyre D, Thabane L, Samaan Z: **The association of attempted suicide with genetic variants in the SLC6A4 and TPH genes depends on the definition of suicidal behavior: a systematic review and meta-analysis.** *Transl Psychiatr* 2012, **2**(2):96.
26. Swartz MK: **The PRISMA statement: a guideline for systematic reviews and meta-analyses.** *J Pediatr Health Care* 2011, **25**(1):1–2. doi: 10.1016/j.pedhc.2010.09.006.
27. Moher D, Liberati A, Tetzlaff J, Altman DG: **Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.** *Open Med* 2009, **3**(3):21.
28. Baud P, Perroud N, Courtet P, Jaussent I, Relecom C, Jollant F, Malafosse A: **Modulation of anger control in suicide attempters by TPH-1.** *Genes Brain Behav* 2009, **8**(1):97–100.
29. Serretti A, Chiesa A: **Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.** *J Clin Psychopharmacol* 2009, **29**(3):259–266.
30. Kishi T, Yoshimura R, Fukuo Y, Okochi T, Matsunaga S, Umene-Nakano W, Nakamura J, Serretti A, Correll CU, Kane JM, Iwata N: **The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder.** *Eur Arch Psychiatry Clin Neurosci* 2013, **263**(2):105–118.
31. Calati R, Porcelli S, Giegling I, Hartmann AM, Möller H-J, De Ronchi D, Serretti A, Rujescu D: **Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study.** *J Psychiatr Res* 2011, **45**(3):309–321.
32. Gonzalez-Castro TB, Tovilla-Zarate CA, Juarez-Rojop I, Pool Garcia S, Genis A, Nicolini H, Lopez Narvaez L: **Association of 5HT1A gene variants with suicidal behavior: case-control study and updated meta-analysis.** *J Psychiatr Res* 2013, **30**(13):00130–00131.
33. Tovilla-Zarate C, Juarez-Rojop I, Ramon-Frias T, Villar-Soto M, Pool-Garcia S, Medellin BC, Genis Mendoza AD, Narvaez LL, Humberto N: **No association between COMT val158met polymorphism and suicidal behavior: meta-analysis and new data.** *BMC Psychiatry* 2011, **11**(151):11–151.
34. Jernej B, Stefulj J, Hranilovic D, Balija M, Skavic J, Kubat M: **Intronic polymorphism of tryptophan hydroxylase and serotonin transporter: indication for combined effect in predisposition to suicide.** *J Neural Transm* 2004, **111**(6):733–738.
35. Hong CJ, Tsai SJ, Wang YC: **Association between tryptophan hydroxylase gene polymorphism (A218C) and schizophrenic disorders.** *Schizophr Res* 2001, **49**(1–2):59–63.
36. Rujescu D, Giegling I, Bondy B, Gietl A, Zill P, Moller HJ: **Association of anger-related traits with SNPs in the TPH gene.** *Mol Psychiatry* 2002, **7**(9):1023–1029.
37. Souery D, Van Gestel S, Massat I, Blairy S, Adolfsson R, Blackwood D, Del-Favero J, Dikeos D, Jakovljevic M, Kaneva R, Lattuada E, Lerer B, Lilli R, Milanova V, Muir W, Nothen M, Oruc L, Papadimitriou G, Propping P, Schulze T, Serretti A, Shapira B, Smeraldi E, Stefanis C, Thomson M, Van Broeckhoven C, Mendlewicz J: **Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study.** *Biol Psychiatry* 2001, **49**(5):405–409.
38. Nielsen DA, Virkkunen M, Lappalainen J, Eggert M, Brown GL, Long JC, Goldman D, Linnoila M: **A tryptophan hydroxylase gene marker for suicidality and alcoholism.** *Arch Gen Psychiatry* 1998, **55**(7):593–602.
39. Turecki G, Zhu Z, Tzenova J, Lesage A, Seguin M, Tousignant M, Chawky N, Vanier C, Lipp O, Alda M, Joober R, Benkelfat C, Rouleau GA: **TPH and suicidal behavior: a study in suicide completers.** *Mol Psychiatry* 2001, **6**(1):98–102.
40. Zalsman G, Frisch A, King RA, Pauls DL, Grice DE, Gelernter J, Alsobrook J, Michaelovsky E, Apter A, Tyano S, Weizman A, Leckman JF: **Case control and family-based studies of tryptophan hydroxylase gene A218C polymorphism and suicidality in adolescents.** *Am J Med Genet* 2001, **105**(5):451–457.
41. Butterschön HN, Flint TJ, Foldager L, Qin P, Christoffersen S, Hansen NF, Kristensen IB, Mortensen PB, Borglum AD, Mors O: **An association study of suicide and candidate genes in the serotonergic system.** *J Affect Disord* 2013, **148**(2–3):291–298.
42. Kunugi H, Ishida S, Kato T, Sakai T, Tatsumi M, Hirose T, Nanko S: **No evidence for an association of polymorphisms of the tryptophan hydroxylase gene with affective disorders or attempted suicide among Japanese patients.** *Am J Psychiatry* 1999, **156**(5):774–776.
43. Ono H, Shirakawa O, Nishiguchi N, Nishimura A, Nushida H, Ueno Y, Maeda K: **Tryptophan hydroxylase gene polymorphisms are not associated with suicide.** *Am J Med Genet* 2000, **96**(6):861–863.
44. Yoon HK, Kim YK: **Association between serotonin-related gene polymorphisms and suicidal behavior in depressive patients.** *Prog Neuropsychopharmacol Biol Psychiatry* 2008, **32**(5):1293–1297.
45. Paik I, Toh K, Kim J, Lee C: **TPH gene may be associated with suicidal behavior, but not with schizophrenia in the Korean population.** *Hum Hered* 2000, **50**(6):365–369.
46. Stefulj J, Kubat M, Balija M, Jernej B: **TPH gene polymorphism and aging: indication of combined effect on the predisposition to violent suicide.** *Am J Med Genet B Neuropsychiatr Genet* 2006, **5**(2):139–141.
47. Abbar M, Courtet P, Bellivier F, Leboyer M, Boulenger JP, Castelhou D, Ferreira M, Lambercy C, Mouthon D, Paoloni-Giacobino A, Vessaz M, Malafosse A, Buresi C: **Suicide attempts and the tryptophan hydroxylase gene.** *Mol Psychiatry* 2001, **6**(3):268–273.
48. Viana MM, De Marco LA, Boson WL, Romano-Silva MA, Correa H: **Investigation of A218C tryptophan hydroxylase polymorphism: association with familial suicide behavior and proband's suicide attempt characteristics.** *Genes Brain Behav* 2006, **5**(4):340–345.
49. Ohtani M, Shindo S, Yoshioka N: **Polymorphisms of the tryptophan hydroxylase gene and serotonin 1A receptor gene in suicide victims among Japanese.** *Tohoku J Exp Med* 2004, **202**(2):123–133.
50. Pooley EC, Houston K, Hawton K, Harrison PJ: **Deliberate self-harm is associated with allelic variation in the tryptophan hydroxylase gene (TPH A779C), but not with polymorphisms in five other serotonergic genes.** *Psychol Med* 2003, **33**(5):775–783.
51. Rotondo A, Schuebel K, Bergen A, Aragon R, Virkkunen M, Linnoila M, Goldman D, Nielsen D: **Identification of four variants in the tryptophan hydroxylase promoter and association to behavior.** *Mol Psychiatry* 1999, **4**(4):360–368.
52. Wilson ST, Stanley B, Brent DA, Oquendo MA, Huang YY, Mann JJ: **The tryptophan hydroxylase-1 A218C polymorphism is associated with diagnosis, but not suicidal behavior, in borderline personality disorder.** *Am J Med Genet B Neuropsychiatr Genet* 2009, **5**(2):202–208.
53. Geijer T, Frisch A, Persson ML, Wasserman D, Rockah R, Michaelovsky E, Apter A, Jonsson EG, Nothen MM, Weizman A: **Search for association between suicide attempt and serotonergic polymorphisms.** *Psychiatr Genet* 2000, **10**(1):19–26.
54. Du L, Faludi G, Palkovits M, Bakish D, Hrdina PD: **Tryptophan hydroxylase gene 218A/C polymorphism is not associated with depressed suicide.** *Int J Neuropsychopharmacol* 2000, **3**(3):215–220.
55. Tsai SJ, Hong CJ, Wang YC: **Tryptophan hydroxylase gene polymorphism (A218C) and suicidal behaviors.** *Neuroreport* 1999, **10**(18):3773–3775.
56. Liu X, Li H, Qin W, He G, Li D, Shen Y, Shen J, Gu N, Feng G, He L: **Association of TPH1 with suicidal behaviour and psychiatric disorders in the Chinese population.** *J Med Genet* 2006, **43**(2):e4.
57. Stefulj J, Mokrovic G, Hranilovic D, Bordukalo-Niksic T, Bakula M, Kubat M, Jernej B: **Functional promoter polymorphism of the neuronal isoform of tryptophan hydroxylase (Tph2) in suicide.** *Psychiatry Res* 2011, **186**(2–3):446–447.
58. Mouri K, Hishimoto A, Fukutake M, Shirowa K, Asano M, Nagasaki Y, Ueno Y, Shirakawa O, Nishiguchi N, Maeda K: **TPH2 is not a susceptibility gene for suicide in Japanese population.** *Prog Neuropsychopharmacol Biol Psychiatry* 2009, **33**(8):1546–1550.
59. Must A, Tasa G, Lang A, Vasar E, Koks S, Maron E, Vali M: **Variation in tryptophan hydroxylase-2 gene is not associated to male completed suicide in Estonian population.** *Neurosci Lett* 2009, **453**(2):112–114.
60. Zill P, Preuss UW, Koller G, Bondy B, Soyka M: **SNP- and haplotype analysis of the tryptophan hydroxylase 2 gene in alcohol-dependent patients and alcohol-related suicide.** *Neuropsychopharmacology* 2007, **32**(8):1687–1694.
61. Zhou Z, Roy A, Lipsky R, Kuchipudi K, Zhu G, Taubman J, Enoch MA, Virkkunen M, Goldman D: **Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations.** *Arch Gen Psychiatry* 2005, **62**(10):1109–1118.
62. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufilets B, Samolyk D, Allilaire JF, Feingold J, Mallet J, Malafosse A: **Association between the tryptophan hydroxylase gene and manic-depressive illness.** *Arch Gen Psychiatry* 1998, **55**(1):33–37.
63. Kavvoura FK, Ioannidis JP: **Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls.** *Hum Genet* 2008, **123**(1):1–14.

64. Angles MR, Ocana DB, Medellin BC, Tovilla-Zarate C: **No association between the HTR1A gene and suicidal behavior: a meta-analysis.** *Rev Bras Psiquiatr* 2012, **34**(1):38–42.
65. Gonzalez-Castro TB, Tovilla-Zarate C, Juarez-Rojop I, Pool Garcia S, Velazquez-Sanchez MP, Genis A, Nicolini H, Lopez Narvaez L: **Association of the 5HTR2A gene with suicidal behavior: case-control study and updated meta-analysis.** *BMC Psychiatry* 2013, **13**(25):13–25.
66. Stang A: **Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.** *Eur J Epidemiol* 2010, **25**(9):603–605.
67. Mann JJ: **The serotonergic system in mood disorders and suicidal behaviour.** *Philos Trans R Soc Lond B Biol Sci* 2013, **368**(1615):20120537.
68. Schild AH, Pietschnig J, Tran US, Voracek M: **Genetic association studies between SNPs and suicidal behavior: a meta-analytical field synopsis.** *Prog Neuropsychopharmacol Biol Psychiatry* 2013, **46**:36–42.

doi:10.1186/1471-244X-14-196

Cite this article as: González-Castro *et al.*: Association of TPH-1 and TPH-2 gene polymorphisms with suicidal behavior: a systematic review and meta-analysis. *BMC Psychiatry* 2014 **14**:196.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

